Dr. Brad Taft is a biochemist with deep expertise in nucleic acid detection, qPCR assay development, next-generation sequencing and sample-to-answer systems product development. Most recently he was the Director of R&D at the MiNDERA Corp. where he developed microneedle devices for the capture of human transcriptome from skin. Prior to that he spent a decade working on next-generation sequencing platforms and highly-multiplexed qPCR assay formats.
Brad’s career has spanned from fabrication of nanostructured devices in an academic setting to customer field support of commercial sequencing products in foreign countries. While at NVS Technologies from 2010-2014, he was part of a team that developed a platform allowing for highly multiplexed rapid qPCR detection of viruses from nasal swab samples. He’s an avid cyclist and plays ice hockey in his spare time.
Brad received his PhD in chemistry from Boston College and his B.S. in chemistry from Florida State University. He conducted his Postdoctoral research in the department of electrical and computer engineering at the University of Toronto. His doctoral research focused on DNA capture-probe and nano-surface interactions for analytical applications.